Zobrazeno 1 - 10 of 37 pro vyhledávání: '"Roberto FaggianI"'
1
Akademický článek
The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease
Autor: Laura Cantoro, Rita Monterubbianesi, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Mariangela Allocca, Rocco Cosintino, Roberto Faggiani, Silvio Danese, Gionata Fiorino
Publikováno v: Diagnostics, Vol 13, Iss 20, p 3183 (2023)
Delayed diagnosis is a challenge in the management of inflammatory bowel disease (IBD). Several studies show a significant association between diagnostic delay and disease progression to complications and surgery, especially in Crohn’s disease (CD)
Externí odkaz: https://doaj.org/article/72ff338e06e14845addd9e3f5b5750c3
Zobrazit plný text záznamu
2
Akademický článek
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
Autor: Maria Lia Scribano, Annalisa Aratari, Benedetto Neri, Cristina Bezzio, Paola Balestrieri, Valentina Baccolini, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Rita Monterubbianesi, Alessandro Tullio, Simone Saibeni, Claudio Papi, Livia Biancone, Rocco Cosintino, Roberto Faggiani
Publikováno v: Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: The effectiveness of ustekinumab in patients with refractory Crohn’s disease (CD) has been investigated in several real-world studies. However, very few data concerning the real-life experience in Italy have been reported. Therefore, th
Externí odkaz: https://doaj.org/article/e25840e2a34e43719e5244f3e0c6a54a
Zobrazit plný text záznamu
3
Akademický článek
A prospective study on quality in endoscopic retrograde cholangiopancreatography (ERCP): trend in Italy from the REQUEST study
Autor: Giulio Donato, Pietro Occhipinti, Loredana Correale, Marco Spadaccini, Alessandro Repici, Andrea Anderloni, Alessandro Fugazza, Piergiorgio Mosca, Andrea Tringali, Guido Costamagna, Milutin Bulajic, Giovanni de Pretis, Armando Gabbrielli, Francesco Maria Di Matteo, Roberto Faggiani, Mohammad Ayoubi, Luca De Luca, Paolo Cantù, Matteo Blois, Iginio Dell’Amico, Attilio Maurano, Maria Flavia Savarese, Giampiero Manes, Raffaella Ferraro, Mauro Barberis, Cesare Hassan
Publikováno v: Endoscopy International Open, Vol 09, Iss 10, Pp E1563-E1571 (2021)
Background and study aims Endoscopic retrograde cholangiopancreatography (ERCP) is a complex procedure with a relatively high rate of adverse events. Data on training of operators and fulfillment of quality indicators in Italy are scarce. The goal of
Externí odkaz: https://doaj.org/article/db1343510d934b50a6a38f65527dc489
Zobrazit plný text záznamu
4
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
Autor: Giammarco Mocci, Antonio Tursi, Giovanni Maconi, Giovanni Cataletti, Beatrice Mantia, Mariaelena Serio, Antonella Scarcelli, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Giuseppe Pranzo, Ileana Luppino, Pietro Paese, Walter Elisei, Rita Monterubbianesi, Roberto Faggiani, Antonio Ferronato, Barbara Perini, Edoardo Savarino, Francesca Maria Onidi, Laura Binaghi, Paolo Usai Satta, Elisa Schiavoni, Daniele Napolitano, Franco Scaldaferri, Daniela Pugliese, Roberta Pica, Andrea Cocco, Maddalena Zippi, Stefano Rodino, Ladislava Sebkova, Giulia Rocco, Carlotta Sacchi, Costantino Zampaletta, Federica Gaiani, Gianluigi De Angelis, Stefano Kayali, Libera Fanigliulo, Roberto Lorenzetti, Leonardo Allegretta, Stefano Scorza, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Rodolfo Sacco, Giacomo Forti, Elisabetta Antonelli, Gabrio Bassotti, Chiara Iannelli, Francesco Luzza, Giovanni Aragona, Patrizia Perazzo, Angelo Lauria, Simona Piergallini, Raffaele Colucci, Maria Antonia Bianco, Costantino Meucci, Gianmarco Giorgetti, Valeria Clemente, Serafina Fiorella, Antonio Penna, Antonio De Medici, Marcello Picchio, Alfredo Papa
Publikováno v: Expert Opinion on Biological Therapy. 23:293-304
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be61b98f0d64991714719ae84cc7371
https://doi.org/10.1080/14712598.2023.2185510
Zobrazit plný text záznamu
7
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab
Autor: Giammarco Mocci, S. Rodinò, Nicola Della Valle, Camilla Graziosi, Tiziana Larussa, Irene Maria Bambina Bergna, Walter Elisei, Giovanni Maconi, Francesco Luzza, Giacomo Forti, Rodolfo Sacco, Roberto Faggiani, Roberto Lorenzetti, Leonardo Allegretta, Marcello Picchio, Giuseppe Pranzo, Antonio Penna, Antonio Ferronato, Raffaele Colucci, Ladislava Sebkova, Costantino Zampaletta, Antonio de Medici, Antonio Tursi
Publikováno v: Journal of Gastrointestinal and Liver Diseases. 30:456-461
Background and Aims: Several studies have found Golimumab (GOL) effective and safe in the short-term treatment of ulcerative colitis (UC), but few long-term data are currently available from real world. Our aim was to assess the long-term real-life e
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5254fdcc9d3f10afa9200c6f8fa940
https://doi.org/10.15403/jgld-3992
Zobrazit plný text záznamu
8
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
Autor: Costantino Zampaletta, Alessandro Armuzzi, Laura Turchini, Elisa Schiavoni, Daniela Pugliese, Daniele Napolitano, Mariaelena Serio, Antonella Scarcelli, Ladislava Sebkova, Rodolfo Sacco, Stefano Rodino’, Giuseppe Pranzo, Roberta Pica, Patrizia Perazzo, Cristiano Pagnini, Rita Monterubbianesi, Costantino Meucci, Francesco Luzza, Marco Le Grazie, Camilla Graziosi, Laura Donnarumma, Gianluigi De’ Angelis, Andrea Cocco, Valeria Clemente, Stefania Chiri, Alessia Immacolata Cazzato, Gabrio Bassotti, Antonio Penna, Tiziana Larussa, Roberto Lorenzetti, Katia Lofano, Maria Giovanna Graziani, GianMarco Giorgetti, Federica Gaiani, Giacomo Forti, Roberto Faggiani, Nicola Della Valle, Raffaele Colucci, Maria Antonia Bianco, Giovanni Aragona, Leonardo Allegretta, Italian group for switch of biologics, Alfredo Papa, Franco Scaldaferri, Giovanni Maconi, Marcello Picchio, Walter Elisei, Antonio Ferronato, Antonio Cuomo, Giammarco Mocci, Antonio Tursi
Publikováno v: Journal of gastrointestinal and liver diseases : JGLD. 31(4)
Background and Aims: Adalimumab (ADA) biosimilars have been included into the therapeutic armamentarium of inflammatory bowel disease (IBD); however, comparative data on the efficacy and safety of the different ADA biosimilars after replacing the ADA
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7feac1fe4a2411a0db794e2c784a9372
https://pubmed.ncbi.nlm.nih.gov/36535057
Zobrazit plný text záznamu
10
Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Autor: Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci, Antonio Cuomo, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Federica Gaiani, GianMarco Giorgetti, Maria Giovanna Graziani, Katia Lofano, Roberto Lorenzetti, Tiziana Larussa, Antonio Penna, Roberta Pica, Giuseppe Pranzo, Stefano Rodino’, Antonella Scarcelli, Costantino Zampaletta, Gabrio Bassotti, Alessia Immacolata Cazzato, Stefania Chiri, Valeria Clemente, Andrea Cocco, Gianluigi de’ Angelis, Laura Donnarumma, Roberto Faggiani, Camilla Graziosi, Marco Le Grazie, Francesco Luzza, Costantino Meucci, Rita Monterubbianesi, Cristiano Pagnini, Patrizia Perazzo, Marcello Picchio, Rodolfo Sacco, Ladislava Sebkova, Mariaelena Serio, Daniele Napolitano, Daniela Pugliese, Franco Scaldaferri, Elisa Schiavoni, Laura Turchini, Alessandro Armuzzi, Walter Elisei, Giovanni Maconi, Alfredo Papa
Publikováno v: Inflammatory bowel diseases.
Background Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator. However, comparative data o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d6a57fb486892a84cbed1997d4e7cb
https://pubmed.ncbi.nlm.nih.gov/35820045
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje